The P2X7 receptor gene polymorphism 1513 A → C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 123, Issue 1, 2003, Pages 66-71

  Starczynski, Jane ^a   Pepper, Chris ^b   Pratt, Guy ^a   Hooper, Laura ^a   Thomas, Alun ^b   Hoy, Terry ^c   Milligan, Donald ^a   Bentley, Paul ^b   Fegan, Christopher ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

B cell chronic lymphocytic leukaemia; Bcl 2 family expression; In vitro drug resistance; P2X7 receptor genotype; Prognosis

Indexed keywords

CD38 ANTIGEN; FLUDARABINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PURINE P2X RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; FEMALE; FISHER EXACT TEST; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FAMILY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE FREQUENCY; GENES, BCL-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, PURINERGIC P2; VIDARABINE;

EID: 0141707704     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04563.x     Document Type: Article

References (22)

1. Adinolfi, E., Melchiorri, L., Falzoni, S., Chiozzi, P., Morelli, A., Tieghi, A., Cuneo, A., Castoldi, G., Di Virgilio, F. & Baricordi, O.R. (2002) P2X7 receptor expression in evolutive and indolent forms of chronic lymphocytic leukaemia. Blood, 99, 706-708.
2. Binet, J.L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., Thomas, M., Tchernia, G., Jacquillat, C. & Boivin, P. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, 198-206.
3. Damle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Vinciguerra, V.P., Rai, K.R., Ferrarini, M. & Chiorazzi, N. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukaemia. Blood, 94, 1840-1847.
4. Di Virgilio, F. & Wiley, J.S. (2002) The P2X7 receptor of CLL lymphocytes - a molecule with a split personality. Lancet, 360, 1898-1899.
5. Ferlini, C., Di Cesare, S., Rainaldi, G., Malorni, W., Samoggia, P., Biselli, R. & Fattorossi, A. (1996) Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry, 24, 106-115.
6. Foon, K.A., Rai, K.R. & Gale, R.P. (1990) Chronic lymphocytic leukemia: new insights into biology and therapy. Annals of Internal Medicine, 113, 525-539.
7. Ghia, P., Guida, G., Stella, S., Gottardi, D., Geuna, M., Strola, G., Scielzo, C. & Calligaris-Cappio, F. (2003) The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukaemia (CLL) patients at risk of disease progression. Blood, 101, 1262-1269.
8. Gu, B.J., Zhang, W., Worthington, R.A., Sluyter, R., Dao-Ung, P., Petrou, S., Barden, J.A. & Wiley, J.S. (2001) A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. Journal of Biological Chemistry, 276, 11135-11142.
9. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. & Stevenson, F.K. (1999) Unmutated Ig V (H) genes are associated with a more aggressive form of chronic lymphocytic leukaemia. Blood, 94, 1848-1854.
10. Kitada, S., Andersen, J., Akar, S., Zapata, J.M., Takayama, S., Krajewski, S., Wang, H.-G. Zhang, X., Bullrich, F., Croce, C.M., Rae, K., Hines, J. & Reed, J.C. (1998) Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood, 91, 3379-3389.
11. Kröber, A., Seiler, T. Benner, L., Bruckle, E., Lichter, P., Dohner, H. & Stilgenbauer, S. (2002) VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukaemia. Blood, 100, 1410-1416.
12. Miller, S.A., Dykes, D.D. & Polesky, H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research, 16, 1215.
13. Oscier, D.G., Gardiner, A.C., Mould, S.J., Glide, S., Davis, Z.A., Ibbotson, R.E., Corcoran, M.M., Chapman, R.M., Thomas, P.W., Copplestone, J.A., Orchard, J.A. & Hamblin, T.J. (2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood, 100, 1177-1184.
14. Pepper, C., Hoy, T. & Bentley, D.P. (1997) Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. British Journal of Cancer, 76, 935-938.
15. Pepper, C., Thomas, A., Hoy, T. & Bentley, P. (1999) Chlorambucil resistance in B-cell chronic lymphocytic leukemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. British Journal of Haematology, 104, 581-588.
16. Reed, J.C. (1998) Molecular biology of chronic lymphocytic leukemia. Seminars in Oncology, 25, 11-18.
17. Robertson, L.E., Plunkett, W., McConnell, K., Keating, M.J. & McDonnell, T.J. (1996) Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia, 10, 456-459.
18. Rozman, C. & Montserrat, E. (1995) Chronic lymphocytic leukemia. New England Journal of Medicine, 333, 1052-1057.
19. Stankovic, T., Stewart, G.S., Fegan, C., Biggs, P., Last, J., Byrd, P.J., Keenan, R.D., Moss, P.A.H. & Taylor, A.M.R. (2002) Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukaemia occurs in pregerminal centre cells and results in defective damage response and unrepaired chromosome damage. Blood, 99, 300-309.
20. Thunberg, U., Tobin, G., Johnson, A., Söderberg, O., Padyukov, L., Hultdin, M., Klareskog, L., Enblad, G., Sundström, C., Roos, G. & Rosenquist, R. (2002) Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet, 360, 1935-1939.
21. Vermes, I., Haanen, C., Steffens-Nakken, H. & Reutelingsperger, C. (1995) A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. Journal of Immunological Methods, 184, 39-51.
22. Wiley, J.S., Dao-Ung, L.P., Gu, B.J., Sluyter, R., Shemon, A.N., Li, C., Taper, J., Gallo, J. & Manoharan, A. (2002) A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet, 359, 1114-1119.